Osimertinib is a third-generation inhibitor approved for the treating non-small cell lung malignancy. tumors in preclinical versions.10 Because of the presence of the acrylamide warhead with the capacity of alkylating Cys797,11 afatinib can circumvent ATP competition and therefore overcome the unfavorable impact caused by the current presence of methionine in the gatekeeper position.11 Nevertheless, in… Continue reading Osimertinib is a third-generation inhibitor approved for the treating non-small cell